1. Generics Bulletin
  2. >>Legal & IP

BGMA Denied In Bid To Negotiate Over VPAS Rebate Scheme

Generics And Biosimilars Body Points To ‘Illogical’ Exclusion From UK Government Talks

 
• By Dave Wallace

UK generics and biosimilars industry association the BGMA has been denied in its bid to overturn a government decision to exclude it from formal negotiations over the VPAS rebate scheme.

Denied red stamp with pen signature
The BGMA has seen its bid for judicial review dismissed • Source: Shutterstock

The British Generic Manufacturers Association has described as “extremely disappointing” a UK court decision to dismiss its bid to be formally included in negotiations over the country’s Voluntary Scheme for Branded Medicines Pricing and Access rebate mechanism, which along with original brands also covers branded generics and biosimilars.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

Kabi Pens Agreement To Launch Generic Exparel In 2030 – With A Volume Limit

 
• By Dean Rudge

With sales of $550m last year and a high barrier to entry, Exparel marks an intriguing target for abbreviated new drug application sponsors. Having shot down a US patent last year and won US FDA approval for its ANDA, Jiangsu Hengrui’s US eVenus Pharmaceutical Laboratories subsidiary and partner Fresenius Kabi have just reached a settlement agreement.

Viatris Puts Pen To Paper On $335m Opioid Settlement Agreement

 
• By Dean Rudge

Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.

Spanish Authorities Investigate Sandoz Over Information-Sharing

 
• By Dave Wallace

Spanish competition regulator the CNMC has announced an investigation into Sandoz and its Bexal subsidiary – as well as Alliance Healthcare España and Bluetab Solutions – over sharing sensitive commercial information relating to pharmacy orders for generics.

Glenmark Dodges UK Dapagliflozin Injunction Ahead Of Patent Trial Decision

 
• By Dean Rudge

A UK High Court justice came down on the side of Glenmark in AstraZeneca’s bid to enjoin the firm from launching a generic version of its Forxiga blockbuster before judgment is delivered in the firms’ patent-litigation clash.

More from Generics Bulletin

Lupin Boosts UK Presence Through Renascience Acquisition

 
• By Adam Zamecnik

Lupin’s UK subsidiary acquired the British firm for an undisclosed sum of money, adding further assets into the company’s armamentarium.

Viatris Puts Pen To Paper On $335m Opioid Settlement Agreement

 
• By Dean Rudge

Following recent agreements signed by Hikma and Amneal, Viatris has become the latest company to reach a cash settlement resolving allegations that its practices fuelled the US’ deadly opioid epidemic.

Spanish Authorities Investigate Sandoz Over Information-Sharing

 
• By Dave Wallace

Spanish competition regulator the CNMC has announced an investigation into Sandoz and its Bexal subsidiary – as well as Alliance Healthcare España and Bluetab Solutions – over sharing sensitive commercial information relating to pharmacy orders for generics.